Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435016 | 1.00 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL28451423 | 1.00 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL28451514 | 1.00 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL21061629 | 0.84 | L3MBTL1 (0.82) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL21061969 | 0.84 | L3MBTL1 (0.82) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL21061948 | 0.82 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL29500889 | 0.82 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL21061923 | 0.82 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL21061611 | 0.82 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 | |
| SCHEMBL30435191 | 0.82 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4EPOLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| EP-3724192-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2020-10-21 | — | — | EP | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| WO-2019116324-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | L3MBTL1 3344/4885ALDH1A1 1270/4885KDM4E 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.